Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

PCT LTD to Present at Fourth Annual Robins Equity Research Roundup on September 26, 2018

PCT
Posted on: 27 Sep 18

LITTLE RIVER, South Carolina and PORTLAND, Oregon, Sept. 25, 2018 /PRNewswire/ -- PCT LTD (OTC Pink: PCTL), a leading provider of environmentally safe, non-toxic antimicrobial solutions, has been invited to present at the Fourth Annual Robins Equity Research Roundup, being held on September 25-26, 2018 near Portland, Oregon. The conference is sponsored by the team at Catalyst Research Management Group, RIA.

Each year, Marc Robins personally selects a small group of companies that he introduces to the investing community. The Equity Research Roundup is sponsored by Catalyst Research Management Group, RIA, to offer opportunities for portfolio, hedge, and mutual fund managers, individual investors, and retail brokers to become acquainted with up-and-coming public and private companies. In addition to company presentations from a range of industries, the conference will also facilitate company introductions to influential members of the investment community. PCT LTD CEO Gary Grieco will be presenting at 10:00 AM PDT on September 26th.

PCT LTD will present its unique patented solutions for alleviating many issues associated with microorganisms, including bacteria, viruses and fungi. These problems impact hospitals, schools, hotels as well as the agricultural industry.

Mr. Grieco remarked: "We are pleased to attend to the Equity Research Roundup and to share the progress we have across multiple industries. We believe that Marc Robins' experience advocating for public micro-cap companies and experience in bringing them together with notable members of the investment world will facilitate our investor outreach program."

About PCT LTD

PCT LTD ("PCTL") focuses its business on acquiring, developing and providing sustainable, environmentally safe disinfecting and tracking technologies products. The company acquires and holds rights to innovative products and technologies, which are commercialized through its wholly-owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp). Currently trading on OTC, "PCTL" aspires to and is actively engaged in preparations for up-listing to a national securities exchange. The Company established entry into its target markets with commercially-viable products and now prepares to gain market share.

PCT Corp's business mission is to profitably provide state-of-the-art Electro-Chemical Activation equipment, disinfecting fluid solutions and PCT Corp's patented tracking system to hospitals and other facilities for the documentable remediation of Hospital Acquired Infections (HAI's), as well as to sell ECA fluid solutions to agricultural markets for the remediation, control and suppression of microbial contamination and disease of certain commercial crops. The Company's primary fluid solution, branded Hydrolyte®, is an EPA registered "hospital-level" disinfectant (United States EPA Registration No. 92108-1) and its proprietary equipment with patented RFID material tracking technology (PCT Annihilyzer® System) is certified under the Green Seal program, which is based on Green Seal standards, which contain stringent performance, health, and sustainability criteria. PCT Corp.'s equipment product line includes:1) PCT Hydrolyte® Generators, 2) PCT Annihilyzer® Systems, and 3) SurvivaLyte® equipment. PCT Corp's unique and patented systems and human-safe products provide next-generation cleaning, sanitizing, disinfecting and decontaminating fluid solutions to the ever-present problems of microbial infection and infestation.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward-looking statements."

Such statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Such statements involve risks and uncertainties, including but not limited to: any implied or perceived benefits resulting from the information disclosed above; risks and effects of legal and administrative proceedings and government regulation; future financial and operational results; competition; general economic conditions; and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated.

Important factors that could cause actual results to differ materially from the forward-looking statements PCTL makes in this press release include market conditions and those set forth in reports or documents it files from time to time with the SEC. PCTL undertakes no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact:
Brokers and Analysts
Chesapeake Group
+1-410-825-3930
info@chesapeakegp.com

Gary Grieco
CEO Paradigm Convergence Technologies
+1-843-390-7900
ggrieco@para-con.com  

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 27/09/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.